Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients

BMC Cancer

Table 1 Clinicopathological features according to HER2 status (n = 447)

		HER2 status
Clinicopathological feature		IHC(3+) ^a	IHC(2+)FISH(+) ^a	P -value
n		398	49
Age (mean)		56.7	54.1	0.227
Tumor size	pTis^b	54	3	0.059
	pT1	215	23
	pT2	110	22
	pT3	19	1
Lymph node metastasis	Positive	96	14	0.527
	Negative	297	35
	Not evaluated	5	0
Histology	NST	350	43	0.970
	Special type	48	6
Tumor grade^c	High	121	10	0.130
	Low/intermediate	256	37
	Not evaluated	21	2
Ki67 LI (%) (mean)^c		48.8	42.8	0.133
ER^c	Positive	245	43	< 0.001
	Negative	153	6
PGR^c	Positive	178	34	0.001
	Negative	220	15
Chemotherapy	Yes	281^d	37^e	0.474
	A + T	155	16
	A only	111	18
	T only	15^f	3
	No	117	12
Anti-HER2 therapy	Yes	288	40	0.166
	Tra	255	34
	Tra + Per	33	6
	No	110	9
Endocrine therapy	Yes	237	40	0.003
	No	161	9

A anthracycline, LI labelling index, NST no special type, Per pertuzumab, T taxane, Tra trastuzumab
^a Presented as number unless otherwise noted to be mean
^b Indicates no remnant invasive disease after NAC
^c Assessed on biopsy for neo-adjuvant chemotherapy (NAC) cases
^d,e Includes 120 and 14 patients who received NAC, respectively
^f Includes one case who received capecitabine as NAC with trastuzumab, but was given taxane after surgery

ISSN: 1471-2407